|
Diana Brixner is Associate Professor and Chair of the Department of Pharmacotherapy
and Executive Director of the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy in Salt Lake City. Her research interest is in the design and conduct of economic and outcomes research studies to assess the value of pharmaceutical therapy to health care payers. Recent work has included evaluation of the effect of varied co-payment levels on use of pharmaceuticals across five disease states, the pharmacy costs associated with delivery of chemotherapy, assessment of cardiometabolic risk factors and the impact of second generation antipsychotic therapy on weight gain.
Prior to this appointment Dr. Brixner was the Vice President of Health Care Management for Novartis Pharmaceuticals, based in East Hanover New Jersey, from 1994 to 1999. For the next three years she served as Regional Sales Director and then Executive Director of National Managed Care Accounts.
She received her undergraduate degree in pharmacy in 1982 from the University of Rhode Island and her doctorate in medicinal chemistry in 1987 from the University of Utah. Dr. Brixner previously held an adjunct faculty position at the College of Pharmacy at the University of the Sciences in Philadelphia, Pennsylvania.
During her career, she has presented at professional meetings, published over 35 scientific articles, authored two book chapters, has one issued patent and has presented numerous continuing education programs. She has served a two-year term on the Board of Directors of ISPOR, was the inaugural Chair of the Institutional Council and served as Co-chair of the ISPOR Managed Care Special Interest Group. She has also served on the Health Outcomes Committee of the Pharmaceutical Research Manufacturers Association and is a long standing member of the Academy of Managed Care Pharmacy (AMCP).
I welcome an opportunity to build on the strengths of the ISPOR organization by serving as president in 2007-2008. These are exciting times in the global evolution of ISPOR in supporting the scientific assessment of new technologies to deliver optimal health care at reasonable cost. The unification of this philosophy across the globe has never been more apparent, providing an opportunity to further implement the ISPOR vision of education, communication and research through continued international growth. With 53% U.S. and 37% European membership, the recent expansion into the Asian market will make ISPOR the global organization envisioned upon its inception. Having recently attended the second biannual Asian meeting in Shanghai, I observed the high level of interest in education and application of the principles of economics and outcomes to allocate scarce healthcare resources across the Asian countries. As a significant portion of the world's population resides in this region, the potential impact of this market on the global application of the science of the discipline towards global health care policy is clear.
This "globalization" of ISPOR will also have significant impact on the organization itself. As the Asian market embraces ISPOR there will be a significant increase in membership and revenues to fuel the growth of a global ISPOR infrastructure. As the international regions expand their membership, an umbrella of global leadership will be necessary. This will allow individual markets to create regional, membership driven committees to bring their specific country needs forward for implementation by the ISPOR organization as a whole.
TOP
|
